title: Homeopathic Oscillococcinum® for preventing and treating influenza and influenza-like illness.
abstract: BACKGROUND
  Influenza is a highly infectious viral disease that is particularly common in the winter months. Oscillococcinum® is a patented homeopathic medicine that is made from a 1% solution of wild duck heart and liver extract, which is then serially diluted 200 times with water and alcohol.
  
  
  OBJECTIVE
  To determine whether homeopathic Oscillococcinum® is more effective than placebo in the prevention and/or treatment of influenza and influenza-like illness in adults or children.
  
  
  METHODS
  We searched CENTRAL (2014, Issue 8), MEDLINE (1966 to August week 4, 2014), MEDLINE In-Process & Other Non-Indexed Citations (4 September 2014), AMED (2006 to September 2014), Web of Science (1985 to September 2014), LILACS (1985 to September 2014) and EMBASE (1980 to September 2014). We contacted the manufacturers of Oscillococcinum® for information on further trials.
  
  
  METHODS
  Randomised, placebo-controlled trials of Oscillococcinum® in the prevention and/or treatment of influenza and influenza-like illness in adults or children.
  
  
  METHODS
  Three review authors independently extracted data and assessed risk of bias in the eligible trials.
  
  
  RESULTS
  No new trials were included in this 2014 update. We included six studies: two prophylaxis trials (327 young to middle-aged adults in Russia) and four treatment trials (1196 teenagers and adults in France and Germany). The overall standard of trial reporting was poor and hence many important methodological aspects of the trials had unclear risk of bias. There was no statistically significant difference between the effects of Oscillococcinum® and placebo in the prevention of influenza-like illness: risk ratio (RR) 0.48, 95% confidence interval (CI) 0.17 to 1.34, P value = 0.16. Two treatment trials (judged as 'low quality') reported sufficient information to allow full data extraction: 48 hours after commencing treatment, there was an absolute risk reduction of 7.7% in the frequency of symptom relief with Oscillococcinum® compared with that of placebo (risk difference (RD) 0.077, 95% CI 0.03 to 0.12); the RR was 1.86 (95% CI 1.27 to 2.73; P value = 0.001). A significant but lesser effect was observed at three days (RR 1.27, 95% CI 1.03 to 1.56; P value = 0.03), and no significant difference between the groups was noted at four days (RR 1.11, 95% CI 0.98 to 1.27; P value = 0.10) or at five days (RR 1.06, 95% CI 0.96 to 1.16; P value = 0.25). One of the six studies reported one patient who suffered an adverse effect (headache) from taking Oscillococcinum®.
  
  
  CONCLUSIONS
  There is insufficient good evidence to enable robust conclusions to be made about Oscillococcinum® in the prevention or treatment of influenza and influenza-like illness. Our findings do not rule out the possibility that Oscillococcinum® could have a clinically useful treatment effect but, given the low quality of the eligible studies, the evidence is not compelling. There was no evidence of clinically important harms due to Oscillococcinum®.
authors: British Homeopathic Association, Luton, UK.
authors: Robert T
authors: RT
authors: Mathie
authors: Joyce
authors: J
authors: Frye
authors: Peter
authors: P
authors: Fisher
mesh_terms: D000818:Animals; D004372:Ducks; D006705:Homeopathy / Q000379:methods*; D006801:Humans; D007252:Influenza Vaccines / Q000627:therapeutic use; D007251:Influenza, Human / Q000517:prevention & control / Q000628:therapy*; D008110:Liver Extracts / Q000627:therapeutic use; D009206:Myocardium; D016032:Randomized Controlled Trials as Topic; D013577:Syndrome; D014020:Tissue Extracts / Q000627:therapeutic use*
chemical_list: D007252:Influenza Vaccines; D008110:Liver Extracts; D014020:Tissue Extracts
references: Homeopathy. 2011 Oct;100(4):288-92
references: 21962205
references: Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001169
references: 16625539
references: Homeopathy. 2010 Jan;99(1):25-36
references: 20129174
references: Cochrane Database Syst Rev. 2012 Jan 18;1:CD002744
references: 22258949
references: J Gen Virol. 2011 Sep;92(Pt 9):2105-2110
references: 21632563
references: Thrombosis. 2012;2012:430460
references: 22195282
references: Lancet Infect Dis. 2012 Jan;12(1):36-44
references: 22032844
references: Complement Ther Med. 2007 Jun;15(2):128-38
references: 17544864
references: Br J Clin Pharmacol. 1989 Mar;27(3):329-35
references: 2655683
references: Cochrane Database Syst Rev. 2004;(1):CD001957
references: 14973976
references: Lancet. 1997 Sep 20;350(9081):834-43
references: 9310601
references: J Altern Complement Med. 2006 Jun;12(5):437-43
references: 16813507
references: Cochrane Database Syst Rev. 2000;(2):CD001957
references: 10796675
references: Evid Based Complement Alternat Med. 2007 Jun;4(2):149-63
references: 17549232
references: Histol Histopathol. 2011 Feb;26(2):167-75
references: 21154230
references: Cochrane Database Syst Rev. 2014 Apr 10;(4):CD008965
references: 24718923
references: BMJ. 2009 Dec 08;339:b5106
references: 19995812
references: Rev Epidemiol Sante Publique. 1995;43(4):380-2
references: 7667544
references: Cochrane Database Syst Rev. 2012 Dec 12;12:CD001957
references: 23235586
references: Homeopathy. 2009 Oct;98(4):186-97
references: 19945674
references: JAMA. 2005 Feb 23;293(8):987-97
references: 15728170
references: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001957
references: 16855981
references: Forsch Komplementmed. 2006;13 Suppl 2:19-29
references: 16883077
references: Ann Ist Super Sanita. 2012;48(1):105-9
references: 22456024
references: Int J Clin Pract. 2004 Sep;58(9):827-32
references: 15529515